Humanigen, the clinical stage biopharmaceutical company focused on preventing and treating cytokine storm, has reported positive data from the first clinical use of lenzilumab, its humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, in 12 COVID-19 patients.

Patients treated with lenzilumab showed rapid clinical improvement with a median time to recovery and discharge of five days and 100% survival to the data cut-off date.

Furthermore, they demonstrated rapid improvement in oxygenation, temperature, inflammatory cytokines and key hematological parameters consistent with improved clinical outcomes.

Patients who were hospitalised in the Mayo Clinic system showed severe or critical pneumonia as a result of COVID-19 and were viewed as being at high risk of further disease progression.

They needed oxygen supplementation and had elevation in at least one inflammatory biomarker before receiving lenzilumab.

Read More